OBJECTIVE: To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn. SUMMARY BACKGROUND DATA: The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses. METHODS:Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups. RESULTS:Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels. CONCLUSIONS: Low-dose recombinant human growth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.
RCT Entities:
OBJECTIVE: To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn. SUMMARY BACKGROUND DATA: The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses. METHODS: Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups. RESULTS:Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels. CONCLUSIONS: Low-dose recombinant humangrowth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.
Authors: D W Hart; S E Wolf; R Mlcak; D L Chinkes; P I Ramzy; M K Obeng; A A Ferrando; R R Wolfe; D N Herndon Journal: Surgery Date: 2000-08 Impact factor: 3.982
Authors: T A Byrne; T B Morrissey; C Gatzen; K Benfell; T V Nattakom; M R Scheltinga; M S LeBoff; T R Ziegler; D W Wilmore Journal: Ann Surg Date: 1993-10 Impact factor: 12.969
Authors: C Rongen-Westerlaken; J M Wit; S M De Muinck Keizer-Schrama; B J Otten; W Oostdijk; H A Delemarre-van der Waal; M H Gons; A Bot; J L Van den Brande Journal: Eur J Pediatr Date: 1992-07 Impact factor: 3.183
Authors: Heather F Pidcoke; Lisa A Baer; Xiaowu Wu; Steven E Wolf; James K Aden; Charles E Wade Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-04-23 Impact factor: 3.619
Authors: Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon Journal: Best Pract Res Clin Endocrinol Metab Date: 2011-10 Impact factor: 4.690
Authors: Rene Przkora; David N Herndon; Oscar E Suman; Marc G Jeschke; Walter J Meyer; David L Chinkes; Ronald P Mlcak; Ted Huang; Robert E Barrow Journal: Ann Surg Date: 2006-06 Impact factor: 12.969
Authors: Michael M Chen; Stewart R Carter; Brenda J Curtis; Eileen B O'Halloran; Richard L Gamelli; Elizabeth J Kovacs Journal: J Burn Care Res Date: 2017 Jan/Feb Impact factor: 1.845
Authors: Gordon L Klein; Sunil J Wimalawansa; Gayathri Kulkarni; Donald J Sherrard; Arthur P Sanford; David N Herndon Journal: Osteoporos Int Date: 2004-09-28 Impact factor: 4.507
Authors: David W Hart; Steven E Wolf; David L Chinkes; Sofia O Lal; Peter I Ramzy; David N Herndon Journal: Ann Surg Date: 2002-10 Impact factor: 12.969